Table 4 Comparison of the cases wherein disease activity could be evaluated only with sigmoidoscopy and requiring colonoscopy
From: Efficacy of sigmoidoscopy for evaluating disease activity in patients with ulcerative colitis
Patient characteristics | Sigmoidoscopy (n = 462) | Colonoscopy (n = 38) | p Value |
|---|---|---|---|
Sex | 0.784 | ||
 Male, n (%) | 306 (66.2) | 26 (68.4) |  |
 Female, n (%) | 156(33.8) | 12 (31.6) |  |
Mean age (year, range) | 44.43 ± 18.07 | 39.79 ± 18.33 | 0.129 |
Disease duration (month, range) | 37.72 ± 49.31 | 33.11 ± 43.73 | 0.576 |
Disease extent at last examination |  < 0.001 | ||
 Proctitis (n, %) | 200 (43.3) | 6 (2.9) |  |
 Left-sided colitis (n, %) | 138 (29.9) | 10 (6.8) |  |
 Extensive colitis (n, %) | 124 (26.8) | 22 (57.9) |  |
Indication for colonoscopy | 0.831 | ||
 Response after initial diagnosis | 96 (20.8) | 7 (18.4) |  |
 Flare-up | 172 (37.2) | 16 (42.1) |  |
Surveillance (No symptom) | 194 (42.0) | 11 (28.9) | Â |
Total Mayo score | 3.48 ± 3.19 | 4.66 ± 2.93 | 0.022 |
Hospitalization | 0.637 | ||
 Outpatient | 401 (86.8) | 34 (89.5) |  |
 Inpatient | 61 (13.2) | 4 (10.5) |  |
Use of topical 5-ASA | 0.614 | ||
 No | 244 (52.8) | 22 (57.9) |  |
 Yes | 218 (47.2) | 16 (42.1) |  |
Laboratory findings | Â | ||
 CRP (mg/dL) | 1.48 ± 5.33 | 1.16 ± 3.42 | 0.635 |
 Fecal calprotectin (μg/g) | 612.52 ± 775.52 | 805.50 ± 850.50 | 0.576 |